Overview

The Sixth International Conference on Cell Therapy for Cardiovascular Disease is a three-day program dedicated to the evolving field of cell-based therapies for cardiac repair and regeneration. During this comprehensive conference, leaders in the field will convene to present their work, experiences, observations, and opinions on the benefits and drawbacks of cell-based therapy.

The conference encompasses all aspects of cell-based therapeutic approaches to cardiovascular diseases. Each day of the conference will focus on the following diseases and the future role of cell-based therapies.

Highlights of the sessions include:

• Disease-specific cell preparations and cell delivery methods
• Angiogenesis, cardiac, and noncardiac applications
• Embryonic vs. adult-derived cells
• Innovations from biotechnology industry
• Tissue engineering, an expanded session focusing on myocardial, coronary, and valve replacement
• Major advances in imaging and specific product applications

CME Accreditation and Designation

The Cardiovascular Research Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cardiovascular Research Foundation designates this educational activity for a maximum of 20.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Documentation of awarded credit is provided for registered attendees in exchange for completed activity evaluations. Certificates of attendance are provided to all registered attendees.

Learning Objectives

After completion of this conference, participants should be able to:

• Identify the scientific basis for cell-based therapies
• Describe new data regarding the capacity of specific cell lineages for cardiac repair
• Recognize the results of clinical studies and the statuses of large-scale efficacy trials
• Discuss the developmental strategies of next-generation cells, engineered tissue, and their expected first-in-human uses
• Recognize the status of cardiovascular stem cell science at the global level, including the development of resources, industry activities, strategies for collaboration, and current applicable policies

Target Audience

This conference is designed for clinicians and clinical investigators, interventional cardiologists, noninvasive cardiologists, cardiac surgeons, research associates, basic science investigators (cell and molecular biologists), members of public and private funding organizations, hospital administrators, program directors, legislators, and regulatory agency personnel.

Activity Evaluation

Evaluation by questionnaire will address content, presentation, possible bias, and future educational needs.